CLAIMS

1. Use of an isolated human antibody or antigen-binding fragment thereof that binds to and neutralizes human TGFβl, TGFβ2 and TGFβ3, in the manufacture of a medicament for treating a patient in need of inhibition of one or more of the human TGFβl, TGFβ2 and TGFβ3, wherein the isolated human antibody or antigen-binding fragment thereof comprises

a heavy chain variable (VH) domain comprising the sequence of SEQ ID NO:1 with asubstitution selected from the group consisting of S30A, S30H, S30W, E74A, E74C, E74D, E74F, E74G, E74H, E74L, E74P, E74Q, E74R, E74S, E74T, E74W, and E74Y; and

a light chain variable (VL) domain comprising the sequence of SEQ ID NO:2.

2. The use according to claim 1, wherein the patient has a fibrotic disease, cancer, or animmune-mediated disease.

3. The use according to claim 1, wherein the patient has renal insufficiency.

4. The use according to claim 1, wherein the patient has focal segmentalglomeruloscl erosis.

5. The use according to claim 1, wherein the patient has idiopathic pulmonary fibrosis.

6. The use according to claim 1, wherein the patient has systemic sclerosis.

7. The use of claim 2, wherein the cancer is breast cancer.

8. The use of claim 2, wherein the cancer is prostate cancer.

9. The use of claim 2, wherein the cancer is ovarian cancer.

10. The use of claim 2, wherein the cancer is stomach cancer.

11. The use of claim 2, wherein the cancer is renal cancer.

12. The use of claim 2, wherein the cancer is pancreatic cancer

13. The use of claim 2, wherein the cancer is colorectal cancer.

14. The use of claim 2, wherein the cancer is skin cancer.

15. The use of claim 2, wherein the cancer is lung cancer.

16. The use of claim 2, wherein the cancer is cervical cancer.

17. The use of claim 2, wherein the cancer is bladder cancer.

18. The use of claim 2, wherein the cancer is glioma.

19. The use of claim 2, wherein the cancer is mesothelioma.

20. The use of claim 2, wherein the cancer is leukemia.

21. The use of claim 2, wherein the cancer is a sarcoma.